Haematological malignancies - Hodgkin lymphoma
Description
- Germinal-centre B-cell malignancy in which the malignant cells are <1% of the tumour mass - the rest is a reactive inflammatory infiltrate
- This is why it is chemo- and radiosensitive, and why checkpoint blockade works
Classical Hodgkin lymphoma (~90%)
| Subtype | Frequency | Notes |
|---|---|---|
| Nodular sclerosis | ~70% | Young adults, mediastinal mass, F=M |
| Mixed cellularity | ~20% | Older, EBV-associated, HIV |
| Lymphocyte-rich | ~5% | Best prognosis |
| Lymphocyte-depleted | <1% | Elderly, HIV, advanced at presentation, worst |
Nodular lymphocyte-predominant (~10%)
- Renamed nodular lymphocyte-predominant B-cell lymphoma (WHO 5th ed) - no longer classified as Hodgkin lymphoma
- LP ("popcorn") cells: CD20+, CD45+, EMA+, CD15-, CD30-
- Indolent, late relapses, transforms to DLBCL in ~5-10%
Immunophenotype - the exam point
| Classical HL | NLPHL | |
|---|---|---|
| CD30 | + | - |
| CD15 | + (~80%) | - |
| CD20 | - / weak | + |
| CD45 | - | + |
| PAX5 | Weak + | Strong + |
6 more sections, plus exam facts
Premium unlocks every note across every specialty, and the full exam fact library behind it.
Get premium access